IDEAYA Biosciences, Inc.

NASDAQ:IDYA

Biotechnology

Healthcare
$26.49 -1.45%

-$0.45 today

Market cap
$2.56B
Beta
-0.05
P/E (TTM)
-19.5
EPS (TTM)
-$1.58
52W Low $20.50High $39.28

Volume 1.45M

Average 1.44M

IDYA Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

IDEAYA Biosciences, Inc.NASDAQ: IDYA

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue remains negative

Q1 FY2026 revenue was $6.56M, compared with $0 a year earlier. Trailing-twelve-month revenue was $225.27M. Over 3 fiscal years it compounded at +62.5% a year.

Context

  • Revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 11 analysts of $45.54M (-79.2%) for the fiscal year ending Dec 2026, a slowdown from the +3024.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.56M-39.7% QoQ
Last fiscal yearDec 2025
$218.71M+3024.4% YoY
LTMMar 2026
$225.27M+3118.1% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+3024.4%-79.2%-3103.6 pp
3-year CAGR+62.5%+7.3%-55.2 pp
5-year CAGR+32.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
218.71M USD
Year-over-year change
+3024.4%
4-year CAGR
+67.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How IDYA compares with its peers on the latest reported figures

  • IDYA's LTM Mar 2026 revenue of $225.27M is the 2nd highest of the 9 companies compared; the peer median is $8.36M.
  • Its year-over-year change of +3118.1% is the highest of 6, against a peer median of +138.9%.
  • Over three fiscal years its annual growth of +62.5% compares with a peer median of +32.7%.
IDYA Competitors Peer median
Revenue for IDYA and competitors
Company Period LTM YoY 3-year CAGR
NRIXNurix Therapeutics, Inc.LTM Aug 2026$701.94M +738.8%+29.5%
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$225.27M +3118.1%+62.5%
VSTMVerastem, Inc.LTM Mar 2026$49.59M +395.8%+128.4%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$28.22M +20.1%+17.1%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$16.72M +138.9%—
RVMDRevolution Medicines, Inc.LTM Jun 2026$0 ——
ERASErasca, Inc.LTM Sep 2026$0 ——
COGTCogent Biosciences, Inc.LTM Jun 2026$0 ——
TNGXTango Therapeutics, Inc.LTM Sep 2026$0 -100.0%+35.9%
Peer median (excluding IDYA) $8.36M+138.9%+32.7%

Competitors are the stored peer set for IDYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue27.94M50.93M23.39M7M218.71M
Cost of Revenue1.73M2.1M4.01M3.83M4.59M
Gross Profit26.22M48.83M19.38M3.17M214.12M
Gross Margin93.8%95.9%82.9%45.2%97.9%
Research & Development58.16M89.54M129.51M294.67M314.7M
Selling, General & Admin18.33M21.8M24.3M35.47M63.32M
Operating Expenses76.48M111.33M153.81M330.14M373.43M
Depreciation & Amortization1.73M2.1M4.01M3.83M4.59M
EBITDA(48.04M)(56.55M)(108.95M)(270.64M)(109.11M)
EBITDA Margin-171.9%-111.0%-465.9%-3866.3%-49.9%
Operating Income(50.27M)(62.5M)(134.43M)(326.98M)(159.31M)
Operating Margin-179.9%-122.7%-574.9%-4671.1%-72.8%
Interest Income506K3.85M21.47M52.5M45.62M
Interest Expense00000
Other Income / Expenses506K3.85M21.47M52.5M45.62M
Income Before Tax(49.76M)(58.66M)(112.96M)(274.48M)(113.7M)
Pre-Tax Margin-178.1%-115.2%-483.0%-3921.1%-52.0%
Income Tax Expense00000
Net Income(49.76M)(58.66M)(112.96M)(274.48M)(113.7M)
Net Margin-178.1%-115.2%-483.0%-3921.1%-52.0%
EPS (Basic)(1.41)(1.42)(1.96)(3.36)(1.28)
EPS (Diluted)(1.41)(1.42)(1.96)(3.36)(1.28)
Weighted Avg Shares35.25M41.44M57.52M81.68M88.49M
Weighted Avg Shares (Diluted)35.25M41.44M57.52M81.68M88.49M

IDEAYA Biosciences, Inc.

NASDAQ:IDYA

Intrinsic Alpha fair value

Locked

Current Price

$26.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.